These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 11773160)

  • 1. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
    Albanell J; Rojo F; Averbuch S; Feyereislova A; Mascaro JM; Herbst R; LoRusso P; Rischin D; Sauleda S; Gee J; Nicholson RI; Baselga J
    J Clin Oncol; 2002 Jan; 20(1):110-24. PubMed ID: 11773160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
    J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.
    Daneshmand M; Parolin DA; Hirte HW; Major P; Goss G; Stewart D; Batist G; Miller WH; Matthews S; Seymour L; Lorimer IA
    Clin Cancer Res; 2003 Jul; 9(7):2457-64. PubMed ID: 12855618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
    Sgambato A; Camerini A; Faraglia B; Ardito R; Bianchino G; Spada D; Boninsegna A; Valentini V; Cittadini A
    J Cell Physiol; 2004 Oct; 201(1):97-105. PubMed ID: 15281092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
    Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
    J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.
    Chan KC; Knox WF; Gee JM; Morris J; Nicholson RI; Potten CS; Bundred NJ
    Cancer Res; 2002 Jan; 62(1):122-8. PubMed ID: 11782368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.
    Albanell J; Rojo F; Baselga J
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):56-66. PubMed ID: 11706397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
    Heimberger AB; Learn CA; Archer GE; McLendon RE; Chewning TA; Tuck FL; Pracyk JB; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2002 Nov; 8(11):3496-502. PubMed ID: 12429640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells.
    Matheny KE; Barbieri CE; Sniezek JC; Arteaga CL; Pietenpol JA
    Laryngoscope; 2003 Jun; 113(6):936-9. PubMed ID: 12782800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
    Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
    Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
    Malik SN; Siu LL; Rowinsky EK; deGraffenried L; Hammond LA; Rizzo J; Bacus S; Brattain MG; Kreisberg JI; Hidalgo M
    Clin Cancer Res; 2003 Jul; 9(7):2478-86. PubMed ID: 12855621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
    Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
    J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZD1839 (IRESSA) stabilizes p27Kip1 and enhances radiosensitivity in cholangiocarcinoma cell lines.
    Yabuuchi S; Katayose Y; Oda A; Mizuma M; Shirasou S; Sasaki T; Yamamoto K; Oikawa M; Rikiyama T; Onogawa T; Yoshida H; Ohtuska H; Motoi F; Egawa S; Unno M
    Anticancer Res; 2009 Apr; 29(4):1169-80. PubMed ID: 19414361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells.
    Chang GC; Hsu SL; Tsai JR; Liang FP; Lin SY; Sheu GT; Chen CY
    Biochem Pharmacol; 2004 Oct; 68(7):1453-64. PubMed ID: 15345335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.